LH logo

Labcorp Holdings Inc. Stock Price

NYSE:LH Community·US$25.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

LH Share Price Performance

US$309.20
45.35 (17.19%)
US$326.81
Fair Value
US$309.20
45.35 (17.19%)
5.4% undervalued intrinsic discount
US$326.81
Fair Value
Price US$309.20
AnalystConsensusTarget US$326.81

LH Community Narratives

·
Fair Value US$326.81 5.4% undervalued intrinsic discount

LH: Share Repurchases And Alzheimer’s Test Launch Will Drive Profits Ahead

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

LH logo

LH: Genetic Testing Expansion And Buybacks Will Support Measured Long Term Upside

Fair Value: US$326.81 5.4% undervalued intrinsic discount
4 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with proven track record.

1 Risk
4 Rewards

Labcorp Holdings Inc. Key Details

US$14.3b

Revenue

US$10.2b

Cost of Revenue

US$4.1b

Gross Profit

US$3.1b

Other Expenses

US$1.0b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
12.39
28.88%
6.99%
67.9%
View Full Analysis

About LH

Founded
1995
Employees
71000
CEO
Adam Schechter
WebsiteView website
www.labcorp.com

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Recent LH News & Updates

Narrative Update Jul 31

LH: Genetic Testing Expansion And Buybacks Will Support Measured Long Term Upside

Analysts have modestly raised their price target for Labcorp Holdings to about $327 from about $310. They cited updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations.

Recent updates

No updates